Publications hub
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
We’re still confirming the best location for some of our content. Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Loading...
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
- (-) Non-prescription medicines (9)
- (-) Listed medicines (7)
- Advisory bodies and committees (362)
- Scheduling (national classification system) (156)
- Prescription medicines (36)
- Advertising (25)
- In Vitro Diagnostic medical devices (IVDs) (24)
- Medicine safety (23)
- Therapeutic goods regulation (20)
- Medical devices safety (13)
- Manufacturing (11)
- Safety (11)
- Complementary medicines (9)
- Over the counter (OTC) medicines (8)
- Regulatory compliance (8)
- COVID-19 vaccines (7)
- COVID-19 (6)
- Medicinal cannabis hub (6)
- Registered complementary medicines (6)
- Assessed listed medicines (5)
- Shortages (4)
- Alert/Advisory (3)
- Fees and payments (3)
- Legislation (3)
- Clinical trials (2)
- Compliance and enforcement hub (2)
- Import and export (2)
- Sunscreens (2)
- Artificial Intelligence (AI) (1)
- Australian Register of Therapeutic Goods (ARTG) (1)
- Biological medicines (1)
- Breast implant hub (1)
- Cosmetics (1)
- Disinfectants/Sterilants (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Pharmacovigilance (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
11 result(s) found, displaying 1 to 11
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 14 March 2024
-
PublicationsWe commissioned the Health Design Lab to conduct market research to better understand the individual consumer, pharmacist and prescriber experiences of shortages and discontinuations.
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closing date: 3 March 2023
-
PublicationsThe TGA Pharmacovigilance Inspection Program (PVIP) metrics report for 2021 is now available.
-
PublicationsOutcomes following review of consultation submissions
-
PublicationsThe PVIP aims to strengthen and broaden the TGA's post-market monitoring activities and protect public health
-
PublicationsIn 2019, the TGA conducted 10 pharmacovigilance inspections of Australian medicine sponsors
-
PublicationsThe TGA has conducted a safety review on coumarin in topical listed medicines
-
PublicationsStatistics from inspections conducted from 1 September 2017 to 31 December 2018
-
PublicationsOTC application placement question and answer tool
-
PublicationsThis Code supersedes the November 1991 edition of the Australian Code of Good Wholesaling Practice for Therapeutic Goods for Human Use.